Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395569 | 0.83 | NPC1 (0.48) | PPARDMAOBMRGPRX4 | |
| SCHEMBL2262271 | 0.80 | LMNA (0.58) | FFAR1MAOBFFAR4ALOX5 | |
| SCHEMBL4833143 | 0.80 | ERN1 (0.54) | S1PR5FFAR1PPARDKDM1AMRGPRX4 | |
| SCHEMBL27863231 | 0.78 | POLB (0.50) | — | |
| SCHEMBL2265075 | 0.78 | MAOB (0.58) | FFAR1MAOBFFAR4ALOX5 | |
| SCHEMBL27882779 | 0.78 | MAOB (0.58) | FFAR1PPARDMAOBERN1 | |
| SCHEMBL1128493 | 0.77 | FFAR1 (0.59) | FFAR1PPARDKDM1AMRGPRX4ALOX5 | |
| SCHEMBL1516640 | 0.77 | S1PR5 (0.45) | SCN9AS1PR5FFAR1PPARDMAOB | |
| SCHEMBL1283846 | 0.76 | FFAR1 (0.58) | FFAR1MAOBFFAR4 | |
| SCHEMBL1300529 | 0.76 | MEN1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | SCN9A 902/4885S1PR5 3968/4885FFAR1 1350/4885 |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | SCN9A 1087/4885S1PR5 3422/4885FFAR1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.